ADAM17 induces the release of soluble VLDLR (sVLDLR), which inhibits the Wnt pathway and leads to macular degeneration in eye tissue, whereas the shedding of sVLDLR is blocked by selective ADAM17 inhibitors (4). Here, ADAM17 is linked to macular degeneration.